Tags

Type your tag names separated by a space and hit enter

Comparative effectiveness of the dexamethasone intravitreal implant in vitrectomized and non-vitrectomized eyes with macular edema secondary to central retinal vein occlusion.
Ophthalmic Surg Lasers Imaging Retina. 2013 Jan-Feb; 44(1):28-33.OS

Abstract

BACKGROUND AND OBJECTIVE

To compare duration and efficacy of the dexamethasone (DEX) intravitreal implant in vitrectomized (pars plana vitrectomy [PPV] group) and non-vitrectomized eyes (control group) with macular edema related to central retinal vein occlusion (CRVO).

PATIENTS AND METHODS

Eyes that received the DEX implant for CRVO related to macular edema were included in a retrospective chart review. Outcomes measured were best-corrected visual acuity (BCVA) and central macular thickness (CMT).

RESULTS

Fifteen eyes were included in the study. Eight of 15 eyes had prior vitrectomy. Mean BCVA was 20/160 in both groups. Baseline mean CMT was 550 μm (PPV group) and 556 μm (control group, P = .70), and improved to 307.5 μm (PPV group) and 316.3 μm (control group) (P = .90) after implant. The BCVA was 20/125 (PPV group) and 20/200 (control group) (P = .60). Time to next procedure was similar in both groups.

CONCLUSIONS

This retrospective study shows similar CMT reductions with DEX implant treatment for CRVO-related macular edema in vitrectomized and non-vitrectomized eyes.

Authors+Show Affiliations

Department of Ophthalmology, University of Cincinnati College of Medicine, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article

Language

eng

PubMed ID

23418731

Citation

Shaikh, Adeel H., et al. "Comparative Effectiveness of the Dexamethasone Intravitreal Implant in Vitrectomized and Non-vitrectomized Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion." Ophthalmic Surgery, Lasers & Imaging Retina, vol. 44, no. 1, 2013, pp. 28-33.
Shaikh AH, Petersen MR, Sisk RA, et al. Comparative effectiveness of the dexamethasone intravitreal implant in vitrectomized and non-vitrectomized eyes with macular edema secondary to central retinal vein occlusion. Ophthalmic Surg Lasers Imaging Retina. 2013;44(1):28-33.
Shaikh, A. H., Petersen, M. R., Sisk, R. A., Foster, R. E., Riemann, C. D., & Miller, D. M. (2013). Comparative effectiveness of the dexamethasone intravitreal implant in vitrectomized and non-vitrectomized eyes with macular edema secondary to central retinal vein occlusion. Ophthalmic Surgery, Lasers & Imaging Retina, 44(1), 28-33. https://doi.org/10.3928/23258160-20121221-09
Shaikh AH, et al. Comparative Effectiveness of the Dexamethasone Intravitreal Implant in Vitrectomized and Non-vitrectomized Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion. Ophthalmic Surg Lasers Imaging Retina. 2013 Jan-Feb;44(1):28-33. PubMed PMID: 23418731.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Comparative effectiveness of the dexamethasone intravitreal implant in vitrectomized and non-vitrectomized eyes with macular edema secondary to central retinal vein occlusion. AU - Shaikh,Adeel H, AU - Petersen,Michael R, AU - Sisk,Robert A, AU - Foster,Robert E, AU - Riemann,Christopher D, AU - Miller,Daniel M, PY - 2012/03/01/received PY - 2012/07/15/accepted PY - 2013/2/20/entrez PY - 2013/2/20/pubmed PY - 2013/7/9/medline SP - 28 EP - 33 JF - Ophthalmic surgery, lasers & imaging retina JO - Ophthalmic Surg Lasers Imaging Retina VL - 44 IS - 1 N2 - BACKGROUND AND OBJECTIVE: To compare duration and efficacy of the dexamethasone (DEX) intravitreal implant in vitrectomized (pars plana vitrectomy [PPV] group) and non-vitrectomized eyes (control group) with macular edema related to central retinal vein occlusion (CRVO). PATIENTS AND METHODS: Eyes that received the DEX implant for CRVO related to macular edema were included in a retrospective chart review. Outcomes measured were best-corrected visual acuity (BCVA) and central macular thickness (CMT). RESULTS: Fifteen eyes were included in the study. Eight of 15 eyes had prior vitrectomy. Mean BCVA was 20/160 in both groups. Baseline mean CMT was 550 μm (PPV group) and 556 μm (control group, P = .70), and improved to 307.5 μm (PPV group) and 316.3 μm (control group) (P = .90) after implant. The BCVA was 20/125 (PPV group) and 20/200 (control group) (P = .60). Time to next procedure was similar in both groups. CONCLUSIONS: This retrospective study shows similar CMT reductions with DEX implant treatment for CRVO-related macular edema in vitrectomized and non-vitrectomized eyes. SN - 2325-8179 UR - https://www.unboundmedicine.com/medline/citation/23418731/Comparative_effectiveness_of_the_dexamethasone_intravitreal_implant_in_vitrectomized_and_non_vitrectomized_eyes_with_macular_edema_secondary_to_central_retinal_vein_occlusion_ L2 - https://www.healio.com/doiresolver?doi=10.3928/23258160-20121221-09 DB - PRIME DP - Unbound Medicine ER -